Go to content
UR Home

KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy

Kullmann, Frank, Hartmann, A., Stöhr, R., Troppmann, Martina and Endlicher, E. (2011) KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy. Oncology 81, pp. 3-8.

[img]
Preview
PDF - Published Version
Download (296kB)
Date of publication of this fulltext: 06 Nov 2019 09:28

at publisher (via DOI)

Other URL: https://www.karger.com/Article/FullText/330194


Abstract

Background: Genetic alterations within the epidermal growth factor receptor (EGFR) pathway, including KRAS mutations, have been demonstrated to be associated with response to EGFR inhibitors like cetuximab in colorectal cancers. Mutations in the KRAS gene have been found in 70–90% of pancreatic cancers. Unfortunately, the addition of cetuximab to chemotherapy did not increase response or survival ...

plus


Export bibliographical data



Item type:Article
Date:2011
Additional Information (public):OA-Komponente aus Allianzlizenz
Institutions:Medicine > Lehrstuhl für Innere Medizin I
Identification Number:
ValueType
10.1159/000330194DOI
Keywords:Pancreatic cancer, Chemotherapy, KRAS mutation, Cetuximab, Gemcitabine, Oxaliplatin
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Status:Published
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Yes
Item ID:40993
Owner only: item control page

Downloads

Downloads per month over past year

  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons